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Abstract. This review emphasises the recent developments in metal-catalyzed functionalization using direct 
C-H bond activation of pyrimidinones (uracils), quinazolinones and quinazolinone-based fused             
poly-N-heterocycles as well as metal-catalyzed C-H functionalization of high valuable 2-arylquinazolinones. 
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1. Introduction 
Pyrimidinones as well as fused pyrimidinones are an important class of nitrogen-containing 
heterocycles and are considered as privileged cores in medicinal chemistry.1 The pyrimidinones scaffold, 
including uracil derivatives, represents a relevant substructure for a vast array of drug molecules, exhibiting 
a broad spectrum of both biological and pharmacological activities.2 Furthermore, various drugs containing a 
pyrimidinone nucleus are in clinical use as anticancer agents (5-fluorouracil and tegafur)3 or as               
anti-schizophrenia4 (Figure 1). 
 
 
Figure 1 
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The pyrimidin-4-one core is also used as an inhibitor of the enzyme reverse transcriptase to develop 
anti-HIV drugs such as raltegravir (MK0518)5 and dihydro-benzyl-oxopyrimidinones6 (N-DABOs and       
S-DABOs) (Figure 1). Six-member aromatic ring such as pyrimidinone-5-carbonitrile derivatives were also 
reported as anticancer and antimicrobial agents (Figure 2).7 
 
 
Figure 2 
 
Besides pyrimidinones, a recent survey of quinazolinones revealed their occurrence in many bioactive 
alkaloids compounds, isolated from various natural sources, and pharmaceuticals products (Figure 3).8 
Quinazolin-4(3H)-ones are an important class of fused heterocyclic compounds with a wide range of 
therapeutic activities such as anticancer,9 antimicrobial,10 antibacterial,11 antifungal,12 hypotensive, antiviral, 
anti-inflammatory, protein kinase inhibitory activities.13 For exemple, febrifugine,14 isolated from the plant 
Dichroa febrifuga used as a traditional Chinese herbal remedy, is effective against malaria and raltitrexed15 
(Tomudex), which developed by Astra-Zeneca, is an antimetabolite drug used in cancer chemotherapy 
(Figure 3). Based on the aforementioned activities, numerous synthetic strategies for the construction of the 
fused pyrimidinones such as quinazolin-4(3H)-ones have been developed in the recent decade.16 
 
 
Figure 3 
 
In addition, quinazolinone-based fused poly-N-heterocycles are widely found in natural products.17 
They have been shown to be an important class of alkaloids isolated from plant sources, including 
pyrroloquinazolinone derivatives such as luotonin (isolated in 1997 from the plant Peganum nigellastrum)18 
and vasicinone (isolated from Adhatoda vasica),19 indoloquinazolinones such as cruciferane (extracted from 
Isatis indigotic a Chinese biennial herbaceous plant)20 and tryptantrin,21 and the indolopyridoquinazolinone 
rutaecarpine (isolated from Evodia rutaecarpa)22 (Figure 4). The natural quinazolinobenzodiazepine 
alkaloids benzomalvin, sclerotigenin23 and circumdatins24 derivatives isolated from Penicillium sp have also 
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received considerable attention during the lead discovery for neurokinin receptor antagonists. All these 
natural alkaloids have emerged as privileged structures due to their wide-ranging biological activities such as 
antibacterial, antifungal, analgesic, antiobesity, antiviral, anticonvulsant, anti-inflammatory, anti-tumor,  
anti-microbial, antimalarial and antihyperlipidemic activities.25 
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Figure 4 
 
Both synthetic (Figure 5) and natural fused-quinazolinone derivatives (Figure 4) having biological 
properties are already in clinical trials as potential therapeutic agents. For exemple, new            
indazolo[3,2-b]quinazolinone derivatives are potent inhibitors of phosphodiesterase for the treatment of 
asthma and chronic obstructive pulmonary disease26 and synthetic thiazoloquinazolin-9(8H)-ones27 have also 
received considerable attention because of their wide range of biological activities including anticancer 
activity, anti-inflammatory, antifungal, antimicrobial and protein tyrosine kinase inhibitory. 
 
 
Figure 5 
 
Due to their pharmacology and potential therapeutic applications, the development of straightforward 
and innovative synthesis and functionalization of pyrimidinones, quinazolinones and fused quinazolinones is 
still required for organic and medicinal chemists. The direct C-H functionalization of heterocycles has 
become an increasingly valuable tool in complex molecule synthesis without the need for pre-functionalized 
synthetic handles.28 In this context, metal-catalyzed C-H activation has emerged as an important strategy for 
contemporary drug discovery due to the challenges encountered in functionalization of N-bearing ubiquitous 
cyclic framework.29 This late-stage functionalization of drug candidates allow a streamlined route to 
compounds with increased novelty, essential in drug discovery.30 Methods that enable direct modification of 
heterocycles core are among the most efficient to synthetic chemists. This paper presents a review of recent 
metal-catalyzed C-H functionalization of pyrimidinones, quinazolinones and fused quinazolinones 
highlighting these catalytic methodologies offering numerous synthetic benefits.31 
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2. Metal-catalyzed C-H functionalization of pyrimidinones 
2.1. Intramolecular palladium-catalyzed C-H arylation of protected uracils using aryl halides 
Compared with conventional methods, C-H arylation represents a potentially more efficient, atom 
economic and environmentally friendly method. Over the past decade, the direct arylation of unreactive C-H 
bonds of pyrimidinones has emerged as an efficient method for the C(sp2)-C(sp2) bond formation. The 
pioneering example was reported in 2008 by Majumdar32 and described the intramolecular C-H arylation of 
1,3-dialkyluracils, discarding the site-selectivity problem to be feared with these compounds (Scheme 1). 
This palladium-catalyzed intramolecular vinyl C-H arylation strategy gave an easy access to 
benzopyrano[4,3-d]pyrimidine-2,4-diones 1 and benzannulated pyridopyrimidines 2 respectively. The 
methodology was also applied to the synthesis of pyrimido[5,4-c]isoquinolinone-2,4,6-triones 3. 
 
 
Scheme 1 
 
The authors proposed a Heck-type carbopalladation process suggesting that the fairly stabilized -
alkylpalladium intermediate, obtained from the addition of the arylpalladium intermediate to the double 
bond, gave the expected tricyclic products through a -hydrogen elimination. Following this pioneering 
studies, Kim and co-authors33 reported in 2012 the intramolecular C6-H arylation of N-prefunctionalized 
uracils leading to novel benzo[c]pyrimido[1,6-a]azepine scaffold synthesis (Scheme 2). 
 
 
Scheme 2 
 
The authors suggested that a 7-exo-carbopallation of the arylpalladium intermediate took place before 
an epimerization at C-5 position, through the corresponding O-palladium intermediate, which results in the 
formation of the cyclized product by a syn -H elimination process. Further experiments, including a 
palladium-catalyzed Fujiwara-Moritani reaction (see section 2.4.) were conducted on the obtained C5-H 
benzo[c]pyrimido[1,6-a]azepine 4 (R=H) in order to obtain an array of functionalized benzoazepine 
derivatives. 
 
2.2. Intermolecular metal-catalyzed C-H arylation of protected uracils 
The first challenge to be overcome was a regioselective activation of the C5-H or C6-H bond of the 
uracil scaffold. Hocek and co-workers have first reported the intermolecular version using                         
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1,3-dimethyluracil as model substrate for the regioselective C-H arylation.34 The authors’ attention turned to 
investigating how they might steer the reaction to produce exclusively one isomer. The C5/C6 
regioselectivity was controlled by a judicious choice of the catalyst (Scheme 3).35 Thus, the C5-arylated 
uracils 5 were mainly obtained using a palladium-catalyzed C-H activation in the presence of Cs2CO3 as 
base in DMF with aryl iodides or bromides (C5:C6 selectivity >5:1) whilst the C6 selectivity was reached 
when employing CuI as additive. 
 
 
Scheme 3 
 
The same authors further improved the site-selectivity and the scope of the substrate was extended to 
diverse N-protected uracils.36 Among the tested protective groups, benzyl-type substituents such as Bn and 
PMB were found to be the most stable protective groups and led to the corresponding arylated compounds in 
moderate yields whereas the MEM-protected uracil derivatives were obtained in moderate yield. As 
previously reported, the direct C5-H arylation is selectively reached under Cs2CO3-assisted concerted 
metalation-deprotonation (CMD)-based process whereas the direct arylation occurred selectively at C6-H 
site under copper-assisted catalysis (Scheme 4). It was noted that the Copper-mediated reactions in the 
absence of the Pd(II) catalyst gave the expected C6-tolylated uracils in lower yields. 
 
 
Scheme 4 
 
The palladium-catalyzed favored C5-arylation protocols was improved by Kim and co-workers with 
aryl bromides allowing facile installation of diversities into 1,3-dimethyluracil.37 This more efficient 
protocol involved the use of pivaloic acid as proton shuttle. 5-Aryluracil derivatives were formed in 
moderate to good yields most likely via an electrophilic metalation-deprotonation (EMD) process while the 
6-aryl isomers via a Heck-type mechanism as minor products (Scheme 5). Aryl bromides bearing electro-
withdrawing group and 3-bromopyridine could be introduced but in lower yield than described by Hocek36. 
A slight modification was done when bromoanisole derivatives were used as coupling partners. In this case, 
a ligand-less condition was applied in the presence of TBAC in order to make the arylpalladium intermediate 
more electrophilic. 
The C-H arylation reaction was applied to the more sensitive substrate                                                 
1-(tetrahydrofuran-2-yl)-3-benzyluracil, at 100 °C instead of 130 °C to avoid the degradation of the starting 
material, and the C5-phenylated product was isolated in 55% yield as the sole compound (Scheme 6). 
More recently, Wnuk38 disclosed one example of this strategy under milder conditions reaction. The 
authors carried out direct C-H arylation of 1-N-benzyluracil with aryl halides in the presence of TBAB. 
Thus, treatment of 1-N-benzyluracil with 4-iodoanisole (3 equiv) and TBAB/Pd(OAc)2/AgCl at lower 
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temperature than previously reported by Hocek and Kim gave a mixture of the C5 (23%) and C6-arylated 
(33%) uracil products with recovered 1-N-benzyluracil (Scheme 7). The moderate overall yield (56%) and 
the low selectivity must be assigned to the poor electrophilicity of the resulting arylpalladium intermediate, 
even with the presence of silver salt. 
 
 
Scheme 5 
 
 
Scheme 6 
 
 
Scheme 7 
 
A palladium-catalyzed silver-promoted arylation of fused pyrimidinone under aqueous conditions was 
also reported by Guchhait.39 Under these step-economic process, 4H-pyrido[1,2-a]pyrimidin-4-one was    
C3-arylated using aryl iodides or bromides as coupling partners (Scheme 8) leading to target-based 
discovery of potent anticancer agents.40 Several synthesized arylated compounds were found to exhibit 
pronounced human topoisomerase II(hTopoII) inhibitory activities. As demonstrated by relevant 
mechanistic studies, the C-3 arylation undergoes via a concerted metalation deprotonation (CMD) pathway 
triggered by an unusual feature involving the formation of cationic arylpalladium species promoted by halo-
sequestering silver salts. 
The palladium catalyzed C-H arylation of uracils was also reported by Roy in 2014 using arylboronic 
acids instead of aryl halides as coupling partners.41 The authors have developed a regioselective and base-
free protocol for the efficient synthesis of C6-arylated N-protected uracils via oxidative Heck reaction.42 
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Various 6-aryluracil derivatives were exclusively obtained in good yields by a combination of Pd(OAc)2 and 
1,10-phenanthroline as the ligand under oxygen atmosphere in DMF (Scheme 9). 
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Scheme 9 
 
The copper-catalyzed C-H arylation was then investigated by Chien and co-authors to design a 
streamlined and rapid synthetic route to an arylated 1,3-dimethyluracils at C6 position library (Scheme 10).43 
The site-selectivity was obtained using the inexpensive CuBr catalyst in the presence of LiOtBu as the base 
in DMF. These optimized conditions minimized the formation of C5-arylated product as much as the 5,6-
diarylated one. Evaluation of both the steric and electronic effects of a substituent at the C5 position revealed 
a slight decrease in yields for the resulted 5-substituted-6-arylated uracil derivatives. 
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Scheme 10 
 
The sole example of gold-catalyzed C-H arylation of 1,3-dimethyluracil was recently reported by 
Lloyd-Jones.44 The authors have first established a rapid and efficient arylation process for a C-H arylation 
of indole using arylsilane bearing a hydroxypropyldimethylsilyl (HPDMS) group. The undesired oxidation 
of the starting materials with the hypervalent iodine(III) compound was avoided by sterically encumbering 
this oxidant. Applying the optimized conditions to 1,3-dimethyluracil, the C5-arylated compound was 
exclusively obtained using (tht)AuBr3 as catalyst in 78% yield after 1.7h at room temperature (Scheme 11). 
 
2.3. Metal-catalyzed dehydrogenative cross-coupling of pyrimidinones with (hetero)-arenes 
The second approach involves cross-couplings between two inactivated substrates. The earliest report 
containing an example of a modest yielding intermolecular arylation of pyrimidinone appeared in 1989.45 
Since then, this cross-dehydrogenative coupling (CDC) reaction46 has been recently developed and new 
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types of direct intra- and intermolecular C-H activation leading to (hetero)-arylation and vinylation have 
been studied. An example of palladium-catalyzed cross-dehydrogenative coupling (CDC) reactions was first 
reported by Kim and co-authors in 2011. In this study, 1,3-dimethyl-6-phenyluracil was exclusively obtained 
in high yield by oxidative phenylation via a CMD mechanism in the presence of AgOAc (3 equiv) and 
pivaloic acid (6 equiv) at reflux in benzene (Scheme 12).36 This C6-phenylation proceed through a 
regioselective palladation, most likely via a CMD process involving the deprotonation of the more acidic 
hydrogen atom, followed by an arylation of the uracil palladium intermediate with benzene and the reductive 
elimination of Pd(0). 
 
 
Scheme 11 
 
 
Scheme 12 
 
The C6-arylated compound was also obtained using copper-catalyzed C-H bond activation.47 
CuI/phenantroline-catalyzed cross-dehydrogenative coupling of N,N-dimethyluracil with 3-methylanisole 
led selectively to C6-arylated uracil in 61% yield using iodine as a terminal oxidant (Scheme 13). The 
process was supposed to proceed by in situ iodination of one of the coupling partners followed by             
Cu-catalyzed arylation at the most acidic bond (C6-H). 
 
 
Scheme 13 
 
A palladium-catalyzed oxidative homo-coupling of 1,3-dimethyluracil derivatives was reported by 
Kim in 2012.48 A solvent screening was done in order to favor the formation of a dimer, needing the 
competitive aforementioned cross-dehydrogenative coupling36 (CDC) reaction discarded. In almost cases, a 
C5-C5’ dimer was mainly obtained along with a small amount of C5-C6’ dimer (Scheme 14). 
The scope of the oxidative CH/CH homo-coupling was extended to N3-benzyl N1-tetrahydrofuranyl 
derivative and N1-2’,3’,5’-tri-O-benzoyluridine (Scheme 15) to afford exclusively the C5-C5’ isomer in 
moderate yield. 
A palladium-catalyzed regioselective dehydrogenative cross-coupling of N-protected uracils and 
heteroarenes was further reported by Kianmehr. An efficient process for coupling pyridine-N-oxide and 
uracils using Pd(OAc)2 as catalyst in the presence of Ag2CO3 as oxidant was developed (Scheme 16).
49 The 
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reaction took place exclusively at the C-5 position of the uracil and gave access to high valuable 
heteroarylated derivatives. In addition, 3-substitued pyridine-N-oxides are readily introduced with a 
complete selectivity at the C6 position that is the less bulky site in yield ranging from 60% to 85%. 
 
 
Scheme 14 
 
 
Scheme 15 
 
 
Scheme 16 
 
On the basis of the high regioselectivity and in the presence of silver salt, the authors suggested a 
Pd(0)/Pd(II) mechanism for this cross-coupling reaction. Uracil undergoes also a palladium-catalyzed direct 
hetero-arylation with a range of benzofuran derivatives in the presence of K2S2O8 as the oxidant in           
1,4-dioxane at room temperature to give the corresponding 5-arylated uracil analogues (Scheme 17).50 
Nevertheless, the reaction was limited to benzofuran derivatives as coupling partners. In addition, it could be 
noted that the reactions depicted in both schemes 15 and 16 failed with unprotected uracil. 
 
 
Scheme 17 
 
Two examples of intramolecular metal-catalyzed dehydrogenative coupling were described by Roy 
and co-authors. The first one is dealing with a copper-catalyzed dehydrogenative C-H activation/cyclization 
sequence of the 5-amidouracils via the selective activation of uracil C6-H bond under atmospheric oxygen 
and led to various potentially bioactive pyrrolo[3,2-d]pyrimidines (Scheme 18).51 
65 
 
 
 
Scheme 18 
 
In the presence of silver acetate as oxidant, a palladium-catalyzed cross-dehydrogenative coupling 
reaction allowed the straightforward synthesis of uracil-annulated β-carbolinones (Scheme 19).52 
Unprotected indole precursor led to no reaction. A classical electrophilic palladation at the C3 position of the 
indole was envisioned by the authors following by a -bond methathesis reaction to produce a palladacycle 
intermediate which affords the expected tetracyclic compound after reductive elimination. 
 
 
Scheme 19 
 
2.4. Palladium-catalyzed dehydrogenative alkenylation of uracils 
One of the earliest examples highlighting the potential of C-H bond activation by the alkenylation of 
uracil derivatives in an intermolecular fashion with isomerisable alkenes, under palladium-catalysed 
conditions, was reported thirty years ago by Hirota.53 Treatment of N,N-dimethyluracil with methyl acrylate 
and a catalytic amount of palladium acetate using tert-butyl perbenzoate as the reoxidant afforded the 
corresponding 5-alkenyluracil in 75% yield (Scheme 20). This coupling reaction proceeded stereoselectively 
to give exclusively the trans isomer product. 
 
 
Scheme 20 
 
The second exemple of dehydrogenative alkenylation of N-protected uracils was reported more 
recently by Georg.54 The authors developed an efficient regioselective palladium-catalyzed                   
cross-dehydrogenative coupling between uracils and a wide range of alkenes (Scheme 21). 
 
 
Scheme 21 
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The expected 5-alkenyluracils were obtained with absolute stereoselectivity (E-isomers) and various 
functional group were tolerated. These described protocols provide a synthetically useful route for 
alkenylation of this valuable scaffold, required in drug discovery. 
The reaction was successfully extended to uracil-based nucleosides leading to alkenylated uridine and 
2’-deoxyuridine derivatives in 66% and 75% yields respectively (Scheme 22). 
 
 
Scheme 22 
 
Huang and co-workers recently developed a modified eco-friendly process by using the atmospheric 
molecular oxygen as an ecological oxidant instead of an excess of metal oxidant such as silver carbonate 
(Schemes 23 and 24).55 
 
 
Scheme 23 
 
To further examine the versatility of this methodology, the alkenylation was applied to a large number 
of styrene derivatives as coupling partners (Scheme 24). The expected compounds were isolated in yield 
ranging from 28 to 95%. In this case, steric hindrance and electronic effects strongly affected the course of 
the dehydrogenative cross-coupling. According to the aforementioned reported C-H olefination, the free 
NH-uracil was also found to be inefficient for the reaction. 
 
 
Scheme 24 
 
The scope of the coupling partners for the alkenylation was extended to 1,4-quinone by Kianmehr 
(Scheme 25).56 AgNO3 was found to be the most efficient oxidant in this reaction. N,N’-dialkyl and       
N,N’-dibenzyluracils were successfully functionalized with benzoquinone, naphtoquinone and anthraquinone 
whereas N,N’-dibenzoyluracil failed to produce the corresponding alkenylated product. 
The first direct alkenylation of fused pyrimidinone at the C3 position was reported in 2014 by Wang 
and Cao (Scheme 26).57 This strategy involved a synergistic effect of pure oxygen with silver acetate as    
co-oxidant and proceeds with high region- and stereoselectivity. In 2015 a slight modification of the protocol 
described by Liang58 using oxygen as sole oxidant resulted in lower yields (Scheme 27). These strategies 
provide an efficient access to functionalized new 2-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one derivatives. 
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Scheme 25 
 
 
Scheme 26 
 
 
Scheme 27 
 
A palladium-catalyzed Fujiwara-Moritani reaction was also reported on the C5-H 
benzo[c]pyrimido[1,6-a]azepine 4 (depicted in Scheme 2) derivatives with a large excess of ethyl acrylate 
(30 equiv) in the presence of AgOAc and pivaloic acid (Scheme 28).33 
 
 
Scheme 28 
 
2.5. Miscellaneous functionalization of uracils and pyrimidinone 
The recent developments in regioselective metal-catalyzed direct C-H functionalization reactions have 
further enabled streamlined incorporation of a wide range of chemical functionalities that previously were 
difficult to accomplish. For exemple, the selective catalytic trifluoromethylation of uracil was reported in 
2008 by Yamakawa and co-workers for large scale production.59 5-Trifluoromethyluracils, important 
intermediates in the field of medicinal chemistry, were obtained using FeSO4, H2O2 and H2SO4 as catalytic 
system and CF3I as source of trifluoromethyl radical in DMSO. The incorporation of a trifluoromethyl group 
on heteroarenes such as pyrimidin-4-one and N,N-dimethyluracil was described by MacMillan in 2011 
through a radical-mediated mechanism using commercial photocatalyst and a household light bulb (Scheme 
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29).60 The photoredox protocol led to selective trifluoromethylation at the C5 position using CF3SO2Cl as a 
cheap and easy to handle CF3 radical source. 
 
 
Scheme 29 
 
The reaction of N,N-dimethyluracil with Langlois reagent (CF3SO2Na) under radical conditions in the 
presence of tBuOOH at room temperature was also reported by Hocek and led selectively to                       
5-trifluoromethyled uracil 27 in a lower yield (67%) (Scheme 30).61 
 
 
Scheme 30 
 
Among the trifluoromethylation, a palladium-catalyzed oxidative functionalization such as 
acetoxylation62 and phosphorylation63 were described by Kim and co-workers (Scheme 31 and 32). Owing to 
the nucleophilic nature of the carbon atom at the C5 position, 5-acetoxy and 5-phosphorylated uracil 
derivatives are selectively synthesized. In could be noted that both reaction are successfully applied to 
unprotected uracils. The acetoxylation reaction was performed on various uracil derivatives using Pd(OAc)2 
as catalyst and an excess of iodobenzene diacetate as oxidant in acetic acid (Scheme 31). In the case of       
N-benzyl uracil derivatives, the expected 5-acetoxy products were isolated in moderate yields along with 
triacetoxy compounds. 
 
 
Scheme 31 
 
The oxidative cross-coupling between uracil and dialkyl phosphites proceeds in the presence of 
Mn(OAc)3 as oxidant in acetic acid at room temperature (Scheme 32). 
 
 
Scheme 32 
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The plausible mechanism involved the formation of an electrophilic dialkyl phosphonyl radical 
generated by an oxidation of the dialkyl phosphite which reacted with uracil. 
The versatility of this methodology was proved by successfully extending the reaction to                  
2’-deoxyuridine and uridine derivatives (Scheme 33). 
 
 
Scheme 33 
 
3. Metal-catalyzed C-H functionalization of quinazolinones 
Beside pyrimidinone such as uracil, the direct functionalization of quinazolinone scaffold through a  
C-H bond activation was recently developed. The widespread methodologies used in the synthesis of 
functionalized quinazolinones rely mainly upon condensation pathways from anthranilic acid derivatives. 
Indeed, C2-arylquinazolin-4(3H)-ones are highly valuable compounds that are widely found in bioactive 
molecules, pharmaceuticals and natural products. Reflecting this, their syntheses have attracted much 
attention. A literature survey revealed that examples of C-H arylation on quinazolinone scaffold are really 
sparse. However, this methodology is now recognized as an appealing alternative to traditional              
cross-coupling reactions regarding the generation of heteroaryl-metals intermediates, often instable and air 
moisture sensitive. The first examples of palladium-catalyzed C-H arylation of quinazolinone were reported 
as an intramolecular version.64 This reaction was applied to a convenient synthesis of naturally occurring 
alkaloid Luotonins A (Scheme 34) and rutaecarpine (Scheme 35). The palladium-catalyzed intramolecular 
coupling reaction of 3-[2-(2-bromoindol-3-yl)ethyl]-4(3H)-quinazolinone using potassium acetate as base in 
DMF under reflux gave a direct access to rutaecarpine in modest yield. 
 
 
Scheme 34 
 
 
Scheme 35 
 
More recently, Kaliappan described a new route to N‑arylbenzimidazoquinazolinones using copper-
catalyzed cascade amination (Scheme 36).65 This strategy involves a multi-fold C-N bond formation 
between N-anilinoquinazolinones and aryl/heteroaryl halides followed by acetate ligand-assisted 
intramolecular C-H amination. 
The first example of intermolecular palladium-catalyzed C-H arylation of NH-quinazolin-4(3H)-ones 
with aryl chlorides was reported by Kusurkar, in 2013 for the synthesis of Bouchardatine, a cytotoxic 
alkaloid (Scheme 37).66 
The palladium-catalyzed and copper-assisted arylation of C-H bond of quinazolinone derivatives on 
their reaction with various aryl iodides was reported under microwave irradiation67 by Fruit and Besson in 
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2015 (Scheme 38).68 The screened conditions revealed that the choice of the solvent drastically affected the 
yields of desired product. Moderate to good conversions were only observed with DMA and DMF as 
solvent. In addition, the reaction was effective only in the presence of both metal. This ligandless protocol 
was also easily scaled up without a decrease in yield. 
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Scheme 38 
 
The scope of the C2-H arylation was examined with sterically hindered, electron-rich and electron-
poor aryl iodides. The present strategy was tolerant to various functional groups. The procedure was 
enhanced by extending the coupling partners to bromo and chloro derivatives with adapted phosphine 
ligands (Scheme 39).69 
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Heteroarenes are also readily introduced under optimized conditions (Scheme 40). Notably, 2-bromo- 
and 2-chloropyridine derivatives were efficient coupling partners, whereas 2-iodopyridine failed to produce 
the corresponding arylated compound. 
To prove the versatility of this methodology, the scope of the model substrate was studied with various 
N-protected quinazolin-4-ones (Scheme 41) and the phenylation was also extended to pyridopyrimidinones 
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(Scheme 42). N-alkyl and N-aryl quinazolin-4-ones were found to be suitable substrate for the phenylation 
reaction. Nevertheless, one equivalent of CuI was required for a complete conversion in the case of N-alkyl 
derivatives. The reaction could be applied to the four isomers of pyrido-pyrimidinones, affording the 
expected compounds in good yields ranging from 62 to 87%. 
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Scheme 42 
 
Rhodium(III)-catalyzed selective alkylation and arylation (Scheme 43) of                                           
N-pyridinyl-quinazolin-4-one was recently reported by Samanta. using diazocompounds as coupling 
partners.70 The author described one example of each reaction using the diazomalonate and quinone diazide 
respectively under Rh(III)-catalyzed redox-neutral conditions. The regioselectivity was achieved thanks to 
the pyridine directing group. This process represents an attractive strategy for late-stage functionalization of 
quinazolin-4-one scaffold. 
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One exemple of direct C-H alkylation of quinazolinones using manganese acetate and potassium 
cyclobutyltrifluoroborate as a radical precursor was previously reported by Molander in the presence of 
trifluoroacetic acid in a 1:1 mixture of acetic acid/water (Scheme 44).71 The alkylated compound was 
isolated in 59% yield. 
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Scheme 44 
 
4. Metal-catalyzed C-H functionalization of 2-arylquinazolinones 
The first example of oxidative functionalization of 2-aryl-4(3H)-quinazolinones through a C-H 
activation was reported by Yadav in 2012.72 Using the quinazolinone part as a directed group, both electron-
rich and electron-deficient 2-aryl-4-quinazolinones undergo acetoxylation and methoxylation in the presence 
of Pd(OAc)2 and a stoichiometric amount of PhI(OAc)2 as oxidant (Scheme 45). 
 
 
Scheme 45 
 
Over the last five years, the transition metal-catalyzed direct C-H bond activation of                   
2-arylquinazolinones has extended the frontiers in the functionalization of this heterocycle and notably in the 
building of fused systems. Wu and Chen have developed an alternative synthetic pathway to access 
indazolo[3,2-b]quinazolinones by a palladium-catalyzed C-H bond cleavage and C-N bond formation 
reaction of 2-aryl-3-(aryl-amino)quinazolinones (Scheme 46).73 This strategy gave a streamlined approach 
for the synthesis of a new class of small-molecule fluorophores by intramolecular oxidative C-H amination. 
Rhodium(III)-catalyzed intermolecular C-H amination of 2-arylquinazolin-4(3H)-ones derivatives 
using N-alkyl-hydroxylamine derivatives was recently described by Peng (Scheme 47).74 K3PO4 as base in 
toluene or acetonitrile was found to give the best conversion. The scope of the amination shown that the 
reaction is tolerant to electron-donating and electron-withdrawing substituents leading to exclusively the  
2,6-diaminated products. 
The reaction was extended to ortho-substituted 2-arylquinazolinones in order to achieve 
monoamidation products (Scheme 48). When the ortho position is blocked with a methyl group or halogen 
atom, the desired products are obtained in good yield whereas the reaction with a methoxy group completely 
failed to produce the mono-amidated compound. Various N-alkyl-hydroxylamine derivatives reacted 
smoothly to give the corresponding products in yields ranging from 18 to 99%. 
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One exemple of palladium-catalyzed C-H fluorination of 2-phenylquinazolinone was reported by Park 
and Hong using NFSI as mild electrophilic fluorinating reagent under aerobic conditions (Scheme 49).75 
Using the quinazolinone part as inherent directing group, this optimal condition led to the 2-fluorinated 
compound in 91% yield. 
 
 
Scheme 49 
 
Using the quinazolinone core as directing group for the palladium-catalyzed regioselective mono-
arylation, novel quinazolinones, useful for further structure-activity relationship (SAR) studies, were 
synthesized by Mhaske and co-workers (Scheme 50).76 Diarylaiodoniums have been used as coupling 
partners to provide a wide range of potential bioactive compounds. 
Hong and Park75 reported the reaction of diaryliodonium salts as arylating reagent with free             
NH-(2-aryl)-quinazolin-4(3H)-ones for the efficient tandem synthesis of quinazolinone-fused 
phenanthridinones. Based on the regioselectivity observed, the palladium-catalyzed protocol comprises a 
sequential combination of intermolecular C-H arylation and intramolecular C-H amidation, discarding 
competitive ortho di-arylation of the 2-aryl-quinazolin-4(3H)-one scaffold. The quinazolinone-fused 
phenanthridinone derivatives were obtained in excellent yields (Scheme 51). 
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Hajela77 and Peng78 have also independently reported methods for the preparation of     
phenanthridine-fused quinazolinone derivatives by palladium-catalyzed CH and/or N-H bond activation. 
Whereas the first study described an intramolecular bi-aryl coupling reaction starting from                       
2,3-diaryl-2,3-dihydroquinazolin-4(1H)-one derivatives, the last one involved a tandem C-H/N-H arylation 
using 1,2-dihalogenobenzene as coupling partner with free NH-(2-aryl)-quinazolin-4(3H)-ones (Scheme 52). 
 
 
Scheme 52 
 
Ruthenium and Rhodium-catalyzed tandem oxidative coupling and intramolecular aza-Michael 
addition of 2-phenylquinazolin-4-ones with acrylates were respectively developed by Xuan79 (Scheme 53) 
and Peng80 (Scheme 54). These strategies allows an efficient route for the synthesis of highly valuable 
pyrrolo[2,1-b]quinazolin-9(1H)-one motifs, that are widely found in bioactive molecules, pharmaceuticals 
and natural products such as Luotonin.  Reflecting this, their syntheses have attracted much attention. 
The ruthenium-catalyzed C-H functionalization was extended to 2-heteroarylquinazolin-4-ones as 
suitable substrates. The reaction of 2-thienyl or 2-furylquinazolin-4-ones with acrylate derivatives and vinyl 
sulfone gave access to the corresponding vinylation products (Scheme 55). Only 2-thienylquinazolinone led 
to the pyrrolo[2,1-b]quinazolin-9(1H)-one scaffold with methyl acrylate as coupling partner. 
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Scheme 55 
 
More recently, Mhaske described a ruthenium-catalyzed alkenylation using quinazolinone moiety as 
directing group and alkynes as coupling partners. The scope of the mono C-H alkenylation was examined 
with various terminal alkynes using dibenzoyl peroxide as oxidant (Scheme 56).81 
 
 
Scheme 56 
 
To further examine the versatility of this methodology, the reaction was attempted with alkynes 
bearing withdrawing groups and substituted quinazolin-4-ones. When the reaction temperature and time 
were increased, pyrrolo[2,1-b]quinazolin-9(1H)-one derivatives were obtained in up to 66% yield (Scheme 
57). 
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5. Metal-catalyzed C-H functionalization of fused quinazolinones 
Despite the recent advances that have been made in functionalization of ubiquitous pyrimidinone 
scaffold, the development of an attractive challenging orthogonal direct C-H arylation of fused 
quinazolinones remained sparse. Recently, our group reported a palladium-catalyzed and copper assisted 
regioselective C-H arylation and alkenylation of N8-benzyl- and                                                                     
N8-cyclopropyl-thiazolo[5,4-f]quinazolin-9(8H)-ones (Scheme 58).82 Using DBU as base in DMF, the 
selective arylation took place exclusively at the most acidic C-H site. Under these conditions, both phenyl 
iodides and bromides are effective as coupling partners. -deficient heteroarenes are also readily introduced, 
a notable feature with respect to medicinal agent synthesis. 
 
 
Scheme 58 
 
The C2-arylated N8-benzylthiazolo[5,4-f]quinazolin-9(8H)-ones were further successfully arylated at 
the C7 position to afford the corresponding di-arylated products in moderate to good yields after 5 h at 120 
°C under microwave irradiation (Scheme 59). This rewarding stepwise C-H arylation of 
thiazoloquinazolinone gave access to valuable compounds with broad tolerance to substituents on the 
coupling partners. The methodology was enhanced by the development of the challenging one-pot reaction, 
allowing the chromatographic purification step to be discarded. 
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6. Conclusion 
Within the impressive developments that have been made in metal-catalyzed direct C-H arylation of 
nitrogen containing heterocycles, the development of selective challenging direct C-H functionalization 
methodologies of pyrimidinones and fused pyrimidinones remained still of interest. These reported strategies 
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provide a synthetically useful route for late-stage structural diversification of various high valuable scaffold, 
required in drug discovery. Even if palladium-catalyzed arylation with aryl halides is an overwhelming type 
of C-H functionalization of these heteroarenes, this review highlighted the versatility of the metal-catalyzed 
C-H activation and its appealing application in the streamlined synthesis of array of potential bioactive 
compounds. 
 
Acknowledgements 
This research was supported by the Normandie Universtiy and Institut Carnot I2C. The authors are 
gratefully acknowledged the MESR (Ministère de l’Enseignement Supérieur et de la Recherche) and the 
LABEX SynOrg (ANR-11-LABX-0029) for financial support. We also acknowledge Antan Paar France 
SAS for providing the mono-mode and multi-mode microwave reactors (Monowave 300 and Masterwave 
BTR) and for technical support. 
 
Abbreviations 
Bn  Benzyl  
Bz  Benzoyl 
CDC  Cross-dehydrogenative coupling 
CMD  Concerted metalation-deprotonation 
CSA  Camphorsulfonic acid 
DCE  1,2-dichloroethane 
DMF  Dimethylformamide  
DMSO Dimethylsulfoxide 
EMD  Electrophilic metalation–deprotonation 
Fppy  2-(2,4-difluorophenyl)pyridine 
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PMB  p-methoxybenzyl 
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